210 related articles for article (PubMed ID: 8460912)
1. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.
Vance-Bryan K; Guay DR; Gilliland SS; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 1993 Mar; 37(3):436-40. PubMed ID: 8460912
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster.
Guay DR; Vance-Bryan K; Gilliland S; Rodvold K; Rotschafer J
J Clin Pharmacol; 1993 Oct; 33(10):918-22. PubMed ID: 8227461
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
4. Actual body weight-based vancomycin dosing in neonates.
Pokorná P; Šíma M; Černá O; Allegaert K; Tibboel D; Slanař O
J Chemother; 2019 Oct; 31(6):307-312. PubMed ID: 30983533
[TBL] [Abstract][Full Text] [Related]
5. Concordance of Vancomycin Population-Predicted Pharmacokinetics with Patient-Specific Pharmacokinetics in Adult Hospitalized Patients: A Case Series.
Onor IO; Neuliep A; Tran KA; Lambert J; Gillard CJ; Brakta F; Ezebuenyi MC; St James K; Okogbaa JI; Beyl RA
Drugs R D; 2020 Jun; 20(2):83-93. PubMed ID: 32166646
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
7. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years.
Smit C; Goulooze SC; Brüggemann RJM; Sherwin CM; Knibbe CAJ
AAPS J; 2021 Apr; 23(3):53. PubMed ID: 33839974
[TBL] [Abstract][Full Text] [Related]
8. Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.
Le J; Capparelli EV; Wahid U; Wu YS; Romanowski GL; Tran TM; Nguyen A; Bradley JS
Clin Ther; 2015 Jun; 37(6):1340-51. PubMed ID: 26031618
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.
Masich AM; Kalaria SN; Gonzales JP; Heil EL; Tata AL; Claeys KC; Patel D; Gopalakrishnan M
Pharmacotherapy; 2020 Mar; 40(3):211-220. PubMed ID: 31957057
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
12. Decreased vancomycin clearance in patients with congestive heart failure.
Shimamoto Y; Fukuda T; Tominari S; Fukumoto K; Ueno K; Dong M; Tanaka K; Shirasaka T; Komori K
Eur J Clin Pharmacol; 2013 Mar; 69(3):449-57. PubMed ID: 22791272
[TBL] [Abstract][Full Text] [Related]
13. Determining vancomycin clearance in an overweight and obese population.
Leong JV; Boro MS; Winter M
Am J Health Syst Pharm; 2011 Apr; 68(7):599-603. PubMed ID: 21411801
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
15. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
16. Bayesian forecasting of serum vancomycin concentrations in neonates and infants.
Rodvold KA; Gentry CA; Plank GS; Kraus DM; Nickel E; Gross JR
Ther Drug Monit; 1995 Jun; 17(3):239-46. PubMed ID: 7624919
[TBL] [Abstract][Full Text] [Related]
17. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients.
Polard E; Le Bouquin V; Le Corre P; Kérebel C; Trout H; Feuillu A; Le Verge R; Mallédant Y
Ther Drug Monit; 1999 Aug; 21(4):395-403. PubMed ID: 10442692
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
19. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
Pea F; Porreca L; Baraldo M; Furlanut M
J Antimicrob Chemother; 2000 Mar; 45(3):329-35. PubMed ID: 10702552
[TBL] [Abstract][Full Text] [Related]
20. Dosing vancomycin in the super obese: less is more.
Crass RL; Dunn R; Hong J; Krop LC; Pai MP
J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
